

AMENDMENTS TO THE CLAIMS

Claims 1-13. (Cancelled)

14. (Currently amended) A drug for an antibody therapy of cancer having resistance to the antibody drug, which comprises a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme, an antibody druganti-CD20 antibody and a complement, as all of which are active ingredients.

15. (Original) The drug according to claim 14, wherein the hydrolytic enzyme is pepsin.

16. (Previously presented) The drug according to claim 14, wherein degradation rate of the lactoferrin hydrolysate is 6 to 20%.

17. (Previously presented) The drug according to claim 14, wherein the lactoferrin hydrolysate has a number average molecular weight of 500 to 5000.

18-19. (Cancelled)

20. (Currently amended) A drug for an antibody therapy of cancer having resistance to the antibody drug, which comprises the following peptides of (a)a peptide consisting of the amino acid sequence shown as SEQ ID NO: 2 and/or (e)a peptide consisting of the amino acid sequence shown as SEQ ID NO: 3, an antibody druganti-CD20 antibody and a complement, as, all of which are active ingredients:

(a) a peptide comprising an amino acid sequence consisting of the amino acid sequence shown as SEQ ID NO: 2;

(e) a peptide comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 3.

21-22. (Cancelled)

23. (Currently amended) A method of treating cancer having resistance to an antibody drug comprising administering ~~an antibody drug~~anti-CD20 antibody and  $\alpha$ -complement and administering a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme in an amount sufficient to enhance a complement-dependent cytotoxic activity of the antibody druganti-CD20 antibody and/or the complement in an antibody therapy of cancer having resistance to the antibody drug to a subject in need thereof, wherein administration of the lactoferrin hydrolysate is before or after administration of the antibody druganti-CD20 antibody and/or complement or simultaneously with ~~the antibody drug~~anti-CD20 antibody and/or complement.

24. (Cancelled)

25. (Currently amended) A method for enhancing a complement-dependent cytotoxic activity of anti-CD20 antibody~~an antibody drug~~ and/or  $\alpha$ -complement in an antibody therapy of cancer having resistance to the antibody drug using anti-CD20 antibody~~the antibody drug~~ and the complement, which comprises administering anti-CD20 antibody~~an antibody drug~~ and  $\alpha$ -complement and ~~administering~~administering a lactoferrin hydrolysate obtainable by hydrolyzing lactoferrin with a hydrolytic enzyme to a patient in need thereof and which has an action of enhancing the complement-dependent cytotoxic activity of anti-CD20 antibody~~the antibody drug~~ and/or the complement in an antibody therapy of cancer having resistance to the antibody drug, wherein the lactoferrin hydrolysate is administered before or after administration of anti-CD20 antibody~~the antibody drug~~ and/or complement or simultaneously with anti-CD20 antibody~~the antibody drug~~ and/or complement.

26. (Currently amended) A method for enhancing a complement-dependent cytotoxic activity of anti-CD20 antibody~~an antibody drug~~ and/or  $\alpha$ -complement in an antibody therapy of cancer having resistance to the antibody drug using anti-CD20 antibody~~the antibody drug~~ and the complement, which comprises administering anti-CD20 antibody~~an antibody drug~~ and  $\alpha$ -complement and administering ~~the following peptides of (a) a peptide consisting of the amino acid sequence shown as SEQ ID NO: 2 and/or (e) a peptide consisting of the amino acid sequence~~

Application No.: 10/564,302  
Filing Date: January 10, 2006

shown as SEQ ID NO: 3 to a patient in need thereof wherein administration of the peptide(s) is before or after administration of anti-CD20 antibody~~the antibody drug~~ and/or complement or simultaneously with anti-CD20 antibody~~the antibody drug~~ and/or complement;

(a) a peptide comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 2;  
(c) a peptide comprising an amino acid sequence consisting of the sequence shown as SEQ ID NO: 3.